|
EspAddText
EspRemoveText
|
Authorizing Cannabis for Medical Purposes
|
Policy document
|
2020
|
|
EspAddText
EspRemoveText
|
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
|
Parliamentary submission
|
2014
|
|
EspAddText
EspRemoveText
|
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
|
Parliamentary submission
|
2015
|
|
EspAddText
EspRemoveText
|
Bill C-17 An Act to amend the Food and Drugs Act
|
Parliamentary submission
|
2014
|
|
EspAddText
EspRemoveText
|
Bill C-45: The Cannabis Act
|
Parliamentary submission
|
2017
|
|
EspAddText
EspRemoveText
|
Bill C-45: The Cannabis Act
|
Parliamentary submission
|
2018
|
|
EspAddText
EspRemoveText
|
Canada’s lower-risk cannabis use guidelines (LRCUG)
|
Policy endorsement
|
2017
|
|
EspAddText
EspRemoveText
|
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase
|
Parliamentary submission
|
2014
|
|
EspAddText
EspRemoveText
|
Cannabis for Medical Purposes
|
Policy document
|
2019
|
|
EspAddText
EspRemoveText
|
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology - Prescription Drugs: Clinical Trials and Approval
|
Parliamentary submission
|
2012
|
|
EspAddText
EspRemoveText
|
CMA Recommendations on Vaccine Equity and Intellectual Property
|
Parliamentary submission
|
2022
|
|
EspAddText
EspRemoveText
|
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal
|
Parliamentary submission
|
2013
|
|
EspAddText
EspRemoveText
|
CMA response to patented medicines regulations consultations
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
|
Parliamentary submission
|
2017
|
|
EspAddText
EspRemoveText
|
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
|
Parliamentary submission
|
2018
|
|
EspAddText
EspRemoveText
|
CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act
(Vanessa's Law)
|
Response to consultation
|
2015
|
|
EspAddText
EspRemoveText
|
CMA's Submission to the House of Commons Standing Committee on Health: Drug Shortages
|
Parliamentary submission
|
2012
|
|
EspAddText
EspRemoveText
|
CMA's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
|
Parliamentary submission
|
2014
|
|
EspAddText
EspRemoveText
|
CMA's Submission to the Senate Committee on Social Affairs, Science and Technology - Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals
|
Parliamentary submission
|
2012
|
|
EspAddText
EspRemoveText
|
CMA submission to the study of Bill C-37
|
Parliamentary submission
|
2017
|